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Abstract
The current publication aims to review and analyse the ethical aspects and regulations 
to protect the category of vulnerable patients, as defined in the European legislation. 
These patients need special protection and require more detailed approach throughout 
the clinical trials’ life cycle.
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1. Introduction
According to the National Institutes of Health USA, the number of clinical trials shows a sta-
ble trend for growth. Nearly 28% of all clinical trials worldwide are conducted in Europe [1]. 
It is therefore important that clinical trials are regulated legally and monitored with needed 
level of detail. They must also comply with the ethical standards that promote respect for 
human beings and protect their health and well-being.
Often, researchers included patients who are vulnerable and need special protection. The chap-
ter aims to provide an overview of the ethical issues in clinical trials with vulnerable patients.
Based on European legislation, specifically Regulation (EU) No. 536/2014 of the European 
Parliament and Council and ICH GCP E6 (R1), several categories of so-called vulnerable 
groups of patients might be defined:
1. Pregnant or breastfeeding women
2. Minors
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3. Students and employees
4. People suffering from multiple chronic conditions or terminally ill
5. Ethnic minorities
6. Older people
7. Military
8. People affected by mental health disorders
Each of the listed groups has its specific need, which has to be taken into consideration. While 
standard requirements towards clinical trials life cycle are outlined in European legislation, 
some ethical issues related to the vulnerable groups of patients need to be also part of ethical 
codes of conduct or local legislation. These include additional requirements related to the 
objectives of the study, risk-benefit assessment, strict adherence to the study protocol and 
additional steps in the course of obtaining informed consent.
It is important to constantly improve access to treatments available for vulnerable groups. 
Therefore, medical products of significant clinical value should be appropriately studied for 
their effects in these specific populations. Vulnerable groups of patients require more detailed 
approach and in cases when the legislation does not provide needed level of detail or is out-
dated, ethical issues outlined in the chapter could be taken into consideration by members of 
ethics committees and investigational staff.
2. Clinical trials on women of reproductive age, pregnant or 
breastfeeding
Until the early 1990s of the twentieth century, the inclusion of women of reproductive age 
in clinical trials Phases I and II is very limited. One of the reasons behind this is FDA’s 1977 
guideline, which recommended excluding women with childbearing potential from partici-
pating in early phases of drug trials. The recommended exclusion was broadly applied to any 
‘premenopausal female capable of becoming pregnant’, but explicitly did not apply to women 
with life-threatening diseases [2]. The results of such a major limitation were:
• the rights of sick women were limited, as they cannot get timely treatment with more ef-
fective drugs;
• the efficacy of many medical products on the women was unknown, although they were 
prescribed both men and women.
Thus, in 1993, under pressure from the public and the scientific community, FDA issued 
‘Guidelines for the Study and Evaluation of Gender Differences in the Clinical Evaluation of 
Drugs’, according to which women should be allowed to determine for themselves the appro-
priateness of participating in early clinical trials [2].
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In 1998, experts from the World Health Organisation (WHO) and United Nations (UN) issue 
a report ‘Women and Health Mainstreaming the Gender Perspective into the Health Sector’ 
[3]. The report concludes women need to be included in clinical trials, but their participation 
must be accompanied by informed consent.
Thus, the inclusion of women of reproductive age in clinical trials remains a pivotal issue. 
Ethical committees must ensure proportional participation of both sexes in order to obtain 
reliable trial data; however, the inclusion of women in the study should only take place when 
drug safety data is available and measures to protect women's and future offspring’s health 
are undertaken. Women should receive information about the risks on their reproductive 
system and contraception methods during the study. They should immediately inform the 
medical team in the event of planned or already occurred pregnancy.
Studies on pregnant women should only be conducted in cases when the required data can-
not be obtained from another patient’s categories and when the purpose of the study corre-
sponds to the mother’s and foetus’s health needs with minimal risk. It is mandatory that the 
informed consent is obtained, and information about possible consequences for the health of 
the women, foetus or future child is promptly communicated.
Studies related to monitoring pregnancy, childbirth and the postpartum period are usually 
conducted to evaluate the standards and pathologies during pregnancy, childbirth, postpar-
tum and breastfeeding periods. Some of them are targeting diseases arising during preg-
nancy (hypertension, diabetes, etc.). In cases when a standard therapy does not work, it is 
necessary to conduct experimental treatment. In cases when the benefit is minimal and the 
risk for a woman or foetus is indefinite or high, the testing should be stopped. However, 
provided that the test drug is vital for a pregnant woman, her consent may be sufficient to 
implement the experimental therapy—even if the risk to the foetus is unknown or exceeds 
the minimum.
There are no specific guidelines for the inclusion of breastfeeding women. Nonetheless, the 
ethical committee should pay close attention to the safety of the health of breastfed children 
(mother’s own child or the one who gets the breast milk). Medical team should regularly take 
samples from the breast milk and monitor the composition and protein component in colostrum 
or milk.
As defined by European legislation, along with standard requirements, additional conditions 
should be in place for a clinical trial on pregnant or breastfeeding women. Some of them are 
as follows:
• The clinical trial is required to indicate a direct benefit for trial subject (pregnant or breast-
feeding woman, or her embryo or child). The benefit should outweigh the risks involved.
• If the research involves a breastfeeding woman, additional actions need to be taken to en-
sure no negative impact on child’s health.
In cases where there is no direct benefit for the trial subjects (pregnant or breastfeeding 
woman, or her embryo or child), a clinical trial can only be allowed:
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• if it cannot be conducted on other patient groups;
• if it contributes greatly to obtaining results which could be beneficial to pregnant or breast-
feeding women, or other children or embryos;
• if it holds minimal risk to the subjects [4].
3. Clinical trials on minors
In paediatrics, it is often that methods and therapies are applied based on studies con-
ducted on adults. But the results in children are not always the same. Therefore, the 
treatment for children needs to constantly improve and enhance based on clinical trials 
conducted on children population. However, the best interests of the child should be a 
primary consideration.
According to the Convention on the Rights of the Child adopted by the UN General Assembly 
in 20 November 1989, the children have the same rights as adults. Thus, clinical trials on chil-
dren should meet the same requirements needed for such trials on adults. However, due to 
children’s vulnerability, they require special care and additional protection of their interests. 
It is essential to obtain informed consent, assess the risks to the child and minimise the fear 
and pain during the study.
There are two main concepts on the child’s participation in a clinical trial:
• Informed consent
• Assent
For the first time, the term assent is mentioned in the Declaration of Helsinki, which states 
that when a subject deemed legally incompetent, such as a minor child, is able to give assent 
to decisions about participation in research, the investigator must obtain that assent in addi-
tion to the consent of the legally authorised representative [5].
Prior including a child into a clinical trial, his assent needs to be obtained. If such is missing, 
this fact, along with reasonable explanations of the same, needs to be noted in the Informed 
Consent of child’s parents or legally authorised representative. Child’s assent alone is not suf-
ficient; it should always be accompanied with the informed consent of the parents. If a child 
reaches age of legal competency during the trial, his informed consent should be obtained and 
enclosed to the study documentation.
However, the degree of child’s involvement in the decision depends on its age and maturity. 
Ethical committee can determine the age of the child when it can give consent to participate. 
This decision should comply with the local laws. Only the child’s age, however, is not deter-
minative of whether it is capable of giving consent to participate. The level of development, 
intellectual ability and experience may also be decisive. In all cases, trial information pro-
vided to a child needs to be adapted to its age and mental maturity.
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The ethical expertise usually assesses and determines the risks and the benefits of clinical tri-
als. The main principle is that the best interests of the child shall be a primary consideration. 
In practise, risk assessment on children depends on many factors. For example, taking a small 
quantity of blood from a child suffering from haemophilia creates risk, significantly exceed-
ing the minimum. Children suffering from a chronic disease usually perceive easier various 
medical treatments. So they are at less risk compared to children who have no similar experi-
ence in illness.
During clinical trials on children, it is important to reduce and mitigate painful manipula-
tions, by applying effective methods of pain reduction—usage of corresponding equipment 
and personnel trained or experienced in working with children.
Clinical studies on minors would also include some additional requirements:
• No incentives or financial benefits are allowed. The only exception that can be considered 
is a compensation for expenses directly related to the clinical trial.
• The medical condition being treated occurs only in minors population.
• The clinical trial aims to validate data already collected on adult population to confirm it 
can be applied in minors.
• The clinical trial relates directly to a medical condition of a child.
4. Clinical trials on students and employees
When attracting healthy volunteers, it is imperative that they take the decision to partici-
pate in a clinical trial on their own and without pressure. They should receive all needed 
information related to the trial and declare their voluntary informed consent. Volunteers are 
usually compensated for their time, discomfort and possible risks. Thus, ethical commission 
is to make sure that these cash compensations are not unreasonably high and that attracted 
patients are not from category that is easily persuaded and influenced (people with low incomes 
or without education).
Healthy volunteers are usually patients in Phase I clinical trials. The task of this phase is to 
evaluate drug’s safety, determine a safe dosage range, pharmacokinetics and side effects.
The researcher should consider possible action in the event that a patient volunteer gets sick 
or hurt during the tests. These actions must be thoroughly listed in the informed consent 
form:
• Whether the patient will receive medical treatment and at whose expenses in case he gets 
sick or hurt during the course of the study
• Primary point of contact in case of injury
• Opportunity to withdraw from the clinical trial at any time without having to provide any 
justification
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The participation of students and employees in clinical trials is widely discussed. There are 
two ethical issues: whether the decision to participate was completely voluntary and privacy 
concerns.
On the one hand, students’ and employees’ participation in clinical trials conducted on cam-
pus puts under question the free nature of this decision. The student/employee may decide 
to participate in the study with the idea that his/her participation will be beneficial for the 
learning process or work conditions (better grades, good recommendations, etc.). Conversely, 
there is concern that non-participation in the study may have a negative impact on relations 
with the teaching staff or employer.
On the other hand, the ban on students’ and employees’ participation in clinical trials lim-
its their right of choice. Therefore, the Good Clinical Practice highlights the requirement 
to investigator to recruit patients-volunteers exclusively through advertisement of a gen-
eral nature and not through individual approach to minimise any coercion or pressure in 
decision-making.
Another ethical concern is data privacy issue. The researched should guarantee protection 
and confidentiality of personal data of the participants. This may not be so easy to achieve if 
study involves students or employees of medical institution which conducts the trials. In this 
case, there is a conflict of interest as participants in the study are students or employees, and 
the investigational staff is the employer.
5. Clinical trials in emergency situation and on people suffering from 
incurable diseases
In general, clinical trials with patients who require emergency treatment or intensive therapy 
differ from studies with patients in stable condition. These differences are mostly related to 
the problem of obtaining informed consent—the patient has blurred consciousness, unre-
sponsive or unconscious, lack of time and opportunity to discover his legal representatives.
Ethical standards and legislation allow informed consent to be missing in cases where the 
patient’s life is in danger, and alternative ways of treating are missing. In all cases, however, 
the informed consent shall be sought after the performed emergency intervention to continue 
the participation of the subject in the clinical trial.
If the patient or his/her legal representative does not give consent, he/she has the right to 
object to the use of data collected from the clinical study.
The situation is different in clinical trials and treatment of deadly diseases. They suggest 
another category of patients—terminally ill. Such trials are of a great importance, as often 
there are no alternative types of patients that might be involved due to this is not justified 
from the ethical stand point.
It should be borne in mind that it is possible terminally ill patients wrongly to suggest that 
participation in testing is a necessary condition to receive medical care and that it is better to 
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receive any medical care than nothing. Some terminally ill patients consider their participa-
tion in the trial as an opportunity to be helpful to others. It is therefore important that they are 
properly informed and do not participate in the trial based on false assumptions.
Nowadays the topical question is around participation of terminally ill patients in Phase I 
clinical trials from, as medicines in this phase can be dangerous (e.g. a new kind of chemo-
therapy). Despite the researcher’s willingness to be helpful and give positive results of the 
tests, the patient may not improve or even get worse. For this reason, it is very important for 
the patient to be thoroughly informed the potential risks and benefits of the research, without 
giving unnecessary hope. Study participants must be informed whether their participation or 
non-participation in the study is a prerequisite for treatment in a hospital, and whether the 
stay in hospital is at patient’s cost.
The AIDS epidemic boosts new kind of demand—access to investigational drugs. Many ter-
minally ill patients are willing to take investigational drugs in a clinical trial because there is 
no other way to get them—they are either not available or too expensive.
In the United States, there are several examples of treatment use of investigational drugs. In 
1976, the ‘Group C’ treatment was established by agreement between FDA and the National 
Cancer Institute. The purpose of the programme is to distribute investigational drugs to oncol-
ogists to treat cancer under studies outside the controlled clinical trial. Another expanded 
access concept is so-called Parallel Track policy announced by FDA in April 1992, which per-
mits wider access to new drugs for AIDS/HIV-related diseases [6].
In Europe, ‘Compassionate use’ programmes allow a medicinal product, without market-
ing authorisation, to be given to patients with a life-threatening disease when no alterna-
tive authorised treatments exist. The European Regulation 726/2004/EC provides directions 
to ‘compassionate use’ programmes in the European Union. It states that patients must have 
a chronic or life-threatening disease, and the medicinal product must be undergoing assess-
ment in a clinical trial or be in the marketing authorisation stage. However, details around 
authorisation procedures are still missing and ultimately the programmes are governed by 
individual member states [7].
6. Clinical trials on ethnic minorities
Ethical standards suggest unbiased approach to selecting patients—inclusion or exclusion 
criteria should not be based on gender, race or ethnicity. Most diseases are applicable to all 
populations, so the researcher must include the most diverse types of patients. This way the 
results obtained in the course of the study may be useful for all people who are at risk for a 
disease being treated. The researcher should provide clear justifications on inclusion or exclu-
sion of specific populations.
Yet there are diseases that often occur in certain ethnic groups. For example, sickle cell disor-
ders are more common among people whose ancestors have lived in tropical and subtropi-
cal regions. In such studies, the inclusion of patients from specific ethnic minority is a must. 
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Exclusion or under-representation of ethnic groups would be unfair approach, as thus they 
are deprived of the equal benefits of treatment during the study.
An example of abuse and racial discrimination is The Tuskegee Study of Untreated Syphilis in 
the Negro Male (1932–1972). The purpose of this study was to observe the natural progression 
of untreated syphilis in rural African-American men in Alabama, US.
Usually, clinical trials with homogeneous populations are cheaper. The more diverse the group 
of test patients is, the more variables occur throughout clinical study live cycle. Ultimately, all 
this leads to additional costs. Therefore, in cases where patients represent a homogeneous 
group, the study results should be applicable for the same group and not for the population 
in general.
When attracting ethnic minorities, investigator and ethics committee should ensure that:
• patients representing ethnic minorities are not exposed to additional risk;
• in cases when representatives of minorities are poor or illiterate, their rights are protected 
and there is no coercion or undue incentives for their participation in the clinical trial;
• documentation is in a language understandable to the minority patients.
Different racial and ethnic groups experience disease and respond to treatments differently. 
Therefore, it is important that various populations participate in clinical trials to ensure that 
the treatments and interventions are going to be relevant to those populations.
7. Clinical trials on older people
Population ageing is a long-term trend which began several decades ago in Europe [8]. The 
older population (aged 65 years and over) is constantly increasing. As seen on Figure 1, 
European population is projected to continue to age. And therefore, the importance of addi-
tional research on diseases typical for older people is becoming increasingly important.
In general, there is no certain age, after which the patient involvement is not recommended. 
Yet some researchers avoid recruitment of older patients because of certain difficulties they 
entail. Older people tend not to respect the regime of medications, have difficulties to the 
specific requirements of the study, especially when they are in conflict with their daily life 
(diet, daily regime, etc.).
Older people often have problems seeing and hearing, which means more time and effort 
to explain the purpose and conditions of the study. They tend more often to interrupt their 
participation in the trial, suggesting larger initial screening of patients.
Despite the above-mentioned complications, participation of older people in clinical trials is 
absolutely necessary and very important given the overall ageing of the population.
But can the elderly make a conscious choice? It has been known that the elderly people usu-
ally perceive new information worse than younger ones. Older people have a bad memory, 
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and show lower performance in some cognitive functions—hearing, vision, and reaction time. 
Thus, older people need more time to absorb and understand a similar volume of mental 
work than people in younger age.
Thus, in order to ensure that old patients understand and remember information and 
requirements regarding the study, the researcher is advised to split the procedure of obtain-
ing informed consent in two parts. The purpose of the second part is to verify and confirm 
whether the old patient understands and remembers the information obtained in the first 
meeting. Patients who cannot remember important facts about the study should not partici-
pate in the trial.
8. Clinical trials on military
In the past, military participation in clinical trials has been quite common for many reasons—
controlled diet, easy access to patient homogeneity of the population, etc. But the number 
of clinical trials conducted in the past in accordance with the norms and principles of Good 
Clinical Practice is comparatively small.
Figure 1. Population pyramids, EU-28, 2015: provisional; estimate. 2080: projections (EUROPOP2013) (% of the total 
population). Source: Eurostat (online data codes: demo_pjangroup and proj_13npms).
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Examples of some of these studies include radiation exposure, mustard gas experiments and 
lysergic acid diethylamide (LSD) testing in non-volunteer human subjects [9], not to mention 
human experimentations before and during the World War II.
The ethical problem with clinical trials on military population is obvious—the military are in 
a position of subordination and dependency. There are methodological challenges associated 
with these clinical trials:
• Age range limitation does not allow to determine a strategy for prevention and treatment 
of the general population.
• Limited duration of the study group. Often, this is associated with the period of military 
service or contract, as well as frequent redeployments in other locations or divisions.
• Density of settlement contributes to high levels of disease in acute respiratory tract 
infections.
• Specific conditions of life style and daily regimen during military service may be a factor 
that could affect the test results.
Thus, clinical studies on military should be initiated and conducted with the consent of the 
ethical committee only in cases where the data cannot be collected from the civilian popula-
tion or purpose of the test is the prevention or treatment of conditions and/or diseases pecu-
liar to military population.
An example is the study of the probiotic foods with Lactobacillus bulgaricus. Effect of the pro-
biotic foods with Lactobacillus bulgaricus was investigated on 56 sailors from the Bulgarian 
Submarine fleet and 60 pilots from the Air Force of Bulgaria, who were put to extensive men-
tal and physical pressure. There are lots of clinical studies of the use of probiotic food contain-
ing Lactobacillus bulgaricus as a nutritional support and a part of the medical treatment in 
60 cases of severe intoxication accompanied by poly-organic insufficiency. As a result, these 
probiotic foods were included in the regular diet of the pilots from the Air Force of Bulgaria, 
sailors from the Submarine fleet of Bulgaria and of commandos [10].
9. Clinical trials on people affected by mental health disorder
Clinical trials involving patients with psychosocial or cognitive disorders, as well as those suf-
fering from drug or alcohol addiction bring up an ethical question—if these patients are able 
to make their own rational decisions.
People with intellectual or psychosocial disorders are deprived of their legal capacity and put 
under some form of guardianship. There are two main guardianship models: full and partial. 
People under partial guardianship keep their main civil rights but certain capacities are trans-
ferred to a legal representative, such as financial affairs. Those under full guardianship, on the 
other hand, lose almost all of their civil rights.
There are European countries where guardians besides other life spheres are also empowered 
to take decisions on behalf of the individual in regards to health care. Guardian’s consent may 
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result in hospitalisation or medical interventions. This is considered as voluntary, even though 
the consent from the individual concerned is not present. The interventions might even be 
against the individual’s expressed will, however in a legal sense will still be considered as 
voluntary. In other European countries, guardians or other legal representatives cannot make 
health care decisions. However, non-consensual interventions in the psychiatric field are still 
possible in most countries if a doctor finds them necessary and a court confirms the same.
European legislation outlines additional protection requirements towards inclusion of inca-
pacitated patients into clinical trials:
• The informed consent of the legal representative has been obtained; consent must repre-
sent the subject’s presumed will and may be revoked at any time, without detriment to the 
subject.
• Information received during the informed consent process should be adequate in view of 
the patient’s capacity to understand it.
• No incentives or financial inducements are given except compensation.
• There are grounds for expecting that administering the medicinal product to be tested will 
produce a benefit to the patient outweighing the risks or produce no risk at all.
• The clinical trial is essential with respect to incapacitated subjects and data of comparable 
validity cannot be obtained in clinical trials on persons able to give informed consent, or by 
other research methods.
• The incapacitated patient should take part in the informed consent procedure as far as 
possible [4, 11].
In the past years, the so-called paradigm shift in disability policy is widely discussed. This is 
a shift from the deprival of legal capacity to the right to support for exercising legal capacity.
Such example is a person diagnosed with Down’s syndrome applying for a certain service. 
If he/she is provided information in easy-to-read format and adequate time and support, he/
she may be able to understand pros and cons of the service and choose whether or not to use 
it. In this situation, no disability arises. However, if information is provided in standard lan-
guage and no additional effort taken to explain it in a manner adequate to person’s condition, 
disability becomes a fact. The paradigm shift calls for legal, attitudinal and environmental 
changes [12].
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